Gene mutation

Breast cancer cell
#Breast cancer #Cancer research #Gene mutation #National Institute for Health and Care Excellence (NICE) #Regulatory

NICE approves first ESR1-mutated metastatic breast cancer drug

Final draft guidance from the UK’s National Institute for Health and Care Excellence (NICE) recommends the use of elacestrant, the first tailored treatment for locally advanced and metastatic breast cancer with mutations in the ESR1 gene. Specifically, the drug will be available on the NHS to treat post-menopausal women, and… Read More

#Cancer Research #News #Regulatory

Cancer cells
#Cancer research #CAR-T #Gene mutation #Genetics / genomics #Immunotherapy #Interview #Mass spectrometry / NMR #Meet the Researcher #Nautilus #Oncology #Precision medicine #Protein chemistry / Proteomics #Rare cancers

Podcast: New ways of looking at effective cancer treatment

This is the latest episode of the free DDW narrated podcast, titled “New ways of looking at effective cancer treatment”, which covers three articles written for DDW Volume 24 – Issue 2, Spring 2023 of DDW. They are called: “3D Genomics and targeted cancer therapies”, “Democratising… Read More

#News

Cancer cell
#Cancer drug targets #Drug resistance #EMBL European Bioinformatics Institute #Gene mutation #Genetics / genomics #Oncology #Wellcome Sanger Institute

Drug resistance study boosts discovery of next-generation cancer drugs

New research has detailed each type of cancer mutation that causes drug resistance, helping to uncover targets for drug development and identify potential effective second-line therapies. In a new large-scale study, researchers from the Wellcome Sanger Institute, EMBL’s European Bioinformatics Institute (EMBL-EBI), Open Targets, and collaborators… Read More

#Cancer Research #News #Trending News

Genomics
#Cancer drug targets #Gene mutation #Genetics / genomics #Oncology #Wellcome Sanger Institute

‘Cancer-protection’ gene study reveals potential cancer drug targets

Scientists have pinpointed thousands of genetic changes in a gene that may increase a person’s risk of developing breast and ovarian cancer and also identified new potential therapeutic targets. Researchers from the Wellcome Sanger Institute and their collaborators focused on the ‘cancer protection’ gene RAD51C, known… Read More

#Cancer Research #News #Trending News

Gastric cancer
#Astellas Pharma #Gene mutation #MHRA #Monoclonal antibodies #Oncology

First claudin 18.2 biomarker targeted therapy licensed in Britain

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has licensed Astellas’ Vyloy (zolbetuximab), an anti-claudin 18.2 (CLDN18.2) monoclonal antibody. It is licensed in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adult patients with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric… Read More

#News #Regulatory

Child with cystic fibrosis on ventilator
#Cystic fibrosis #Gene mutation #Phase I trial #Sionna Therapeutics

Two Phase I trials to assess NBD1 stabilisers for cystic fibrosis

The first subjects have been dosed in two separate Phase I clinical trials evaluating the safety, tolerability, and pharmacokinetics of Sionna Therapeutics’ SION-719 and SION-451 in healthy volunteers. SION-719 and SION-451 are product candidates from the company’s series of highly potent nucleotide-binding domain 1 (NBD1) stabilisers… Read More

#News

Cancer cell
#AstraZeneca #Breast cancer #EU #Gene mutation #MHRA #Oncology

Capivasertib approved for advanced breast cancer in the UK

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved AstraZeneca’s capivasertib (Truqap) for patients with advanced hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer. It is approved in cancers that have one or more abnormal PIK3CA, AKT1, or PTEN gene, and does… Read More

#News #Regulatory

Fibroblast growth factor receptor 3
#Events #Gene mutation #Preclinical investigations #Tyra Biosciences

Preclinical tests support FGFR3 inhibitor in skeletal dysplasia

Biotechnology company Tyra Biosciences has announced preclinical proof-of-concept results with TYRA-300, an investigational oral fibroblast growth factor receptor 3 (FGFR3) selective inhibitor, in hypochondroplasia (HCH). The results were presented at the 6th Annual Achondroplasia & Skeletal Dysplasia Research Conference (Pharmachon 2024). HCH is a… Read More

#News

Child having a hearing test
#Gene mutation #Gene therapy #Genetic diseases #Hearing Loss #Paediatrics #Rare disease

Gene therapy cures profound genetic deafness within 24 weeks

The investigational gene therapy DB-OTO improved hearing to normal levels in a child (dosed at 11 months of age) within 24 weeks, according to trial data presented at the American Society of Gene and Cell Therapy (ASGCT) annual conference. Initial hearing improvements have also been observed… Read More

#News #Trending News

A strip of 8 PCR tubes on the thermal cycler
#Antisense Oligonucleotides (ASOs) #CAMP4 Therapeutics #Gene mutation #Phase I trial #Rare disease

Potential first-in-class therapeutic for urea cycle disorders enters trial

CAMP4 Therapeutics has dosed the first participant in its Phase I clinical study of CMP-CPS-001, a potential first-in-class therapeutic for the treatment of urea cycle disorders (UCDs). UCDs are a group of rare, severe, inherited metabolic diseases impacting protein metabolism. Mutations in genes encoding urea cycle… Read More

#News

#3D chemistry #AI #Artificial intelligence (AI) #Biologics #Biotechnology #Cell and gene therapy #Contract development and manufacturing organisations #Covid-19 #Gene expression #Gene mutation #Interview #mRNA #Next generation sequencing #Oncology #PharmEnable #RNA sequencing #Single-cell RNA sequencing #Vaccines

Podcast: What trends will speed up the journey from clinic to bedside?

This is the latest episode of the free DDW narrated podcast, titled “What trends will speed up the journey from clinic to bedside?” which covers three written for Volume 23 – Issue 4, Fall 2022 of DDW. They are called: Sitting down with… PharmEnable, Is single-cell… Read More

#News

Blood cancer
#Blood cancer #Gene mutation #Nurix Therapeutics #Oncology #Protein degradation

Protein degrader overcomes resistance in B-cell malignancies

A paper in the journal Science has identified a new class of BTK mutations that are susceptible to NX-2127, a novel BTK and IKZF1/3 degrader.  The study ‘Kinase Impaired BTK Mutations Are Susceptible to Clinical Stage BTK and IKZF1/3 Degrader NX-2127’ elucidates a previously unappreciated oncogenic scaffold function… Read More

#Cancer Research #News

Child with hearing aids
#Akouos #Eli Lilly #Gene mutation #Gene therapy #Hearing Loss #Phase II trial

Gene therapy cures genetic hearing loss

In the first case of its kind, gene therapy has restored hearing in a patient in the United States. Hearing restoration was observed within 30 days of a single administration of AK-OTOF in the initial AK-OTOF-101 Phase I/II study participant. AK-OTOF is a gene… Read More

#News #Trending News

Blood cells
#Blood cancer #Gene mutation #Oncology #University of Cambridge #Wellcome Sanger Institute

Study reveals how genetic mutations combine to cause cancer

UK scientists have uncovered the interplay between cancer-driving genetic mutations and inherited genetic variants in a rare type of blood cancer. In the future, this knowledge could aid drug development and interventions that reduce the risk of disease. Researchers from the Wellcome Sanger Institute,… Read More

#Cancer Research #News

Human brain
#Age-related diseases (ARDs) #Dementia #Gene mutation #Neurodegenerative disorders #Organoids

Organoid research sheds light on gene mutation linked to dementia

New understanding of a gene that is linked to some forms of dementia and other age-related diseases gives scientists fresh hope that action can be taken against these diseases long before the onset of symptoms. The gene – called Angiogenin or ANG – is associated with… Read More

#Editor's Choice #News

Mother helps child to use a nebuliser
#Cystic fibrosis #European Commission #Gene mutation #Genetics / genomics #Paediatrics #Vertex

EU extends paediatric use of combination in cystic fibrosis

A label expansion for Kaftrio (ivacaftor/tezacaftor/elexacaftor) in a combination regimen with ivacaftor for the treatment of cystic fibrosis (CF) has been approved in the European Union (EU). The European Commission has extended use of the therapy to include children with CF aged two through five years old who have at… Read More

#News #Regulatory